PacBio Joins iHope Initiative as First Long-Read Genomic Sequencing Partner
Rhea-AI Summary
PacBio (NASDAQ: PACB) is joining the iHope global rare-disease genomics network as its first long-read sequencing partner to integrate HiFi long-read whole-genome sequencing.
iHope supports more than 1,000 patients annually across 25 clinical sites in 14 countries. Integration is expected to begin in early 2026 and aims to improve detection of challenging variants and support future precision-therapeutic research.
Positive
- HiFi WGS integration into iHope network
- Network reach: 1,000+ patients annually across 25 sites, 14 countries
- Expected start of integration in early 2026
- Supports research into antisense oligonucleotide therapeutic approaches
Negative
- None.
Key Figures
Market Reality Check
Peers on Argus
PACB is up 1.66% while key peers show mixed to negative moves: DCTH -5.94%, RXST -2.37%, SENS -7.23%, with modest gains in SRDX +0.26% and CTKB +0.57%. No peers appeared in the momentum scanner and no same-day peer headlines were flagged, pointing to a stock-specific reaction.
Historical Context
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Feb 02 | Asset sale & refocus | Positive | -8.8% | Completed sale of short-read assets to Illumina, sharpening long-read focus. |
| Jan 27 | Earnings date set | Neutral | +2.0% | Announced timing of Q4 and full-year 2025 earnings call and webcast. |
| Jan 12 | Rare disease collab | Positive | +3.6% | Planned collaboration with n-Lorem and EspeRare using HiFi long-read WGS. |
| Jan 12 | Clinical adoption news | Positive | +3.6% | HiFi WGS adopted as first-line approach in SUDC study of 200 families. |
| Jan 12 | Prelim revenue update | Positive | +3.6% | Reported Q4 2025 revenue of $44.6M and full-year $160.0M with YoY growth. |
Recent positive strategic and clinical updates (rare disease collaborations, preliminary revenue growth) most often coincided with positive price reactions, while the short-read asset sale saw a negative reaction despite balance sheet benefits.
Over the last few months, PACB has emphasized a pivot toward long-read sequencing and rare disease applications. On Jan 12, 2026, it reported preliminary $44.6M Q4 and $160.0M 2025 revenue alongside rare disease collaborations, with shares rising around 3.6%. The Feb 2, 2026 sale of short-read assets brought about $48.1M in net cash but led to an 8.85% decline. Today’s iHope partnership continues the rare-disease, long-read focus seen in January collaborations.
Market Pulse Summary
This announcement deepens PACB’s role in rare-disease genomics by adding HiFi long-read whole-genome sequencing to iHope’s network, which supports over 1,000 patients annually across 25 sites in 14 countries. It extends a recent series of rare-disease collaborations and builds on January’s preliminary revenue update. Investors may watch how quickly integration begins in early 2026, the scale of sample volumes, and how these partnerships translate into sustainable instrument and consumables demand.
Key Terms
whole-genome sequencing medical
long-read sequencing medical
antisense oligonucleotide–based medical
precision care medical
AI-generated analysis. Not financial advice.
Integration of HiFi Long-Read Whole-Genome Sequencing Expands the Collective Capabilities of iHope’s Global Rare Disease Network
MENLO PARK, Calif., Feb. 12, 2026 (GLOBE NEWSWIRE) -- PacBio (NASDAQ: PACB), a leading provider of high-quality, long-read sequencing technologies, today announced a collaboration with iHope, a global rare disease genomics program of Genetic Alliance, to integrate PacBio’s HiFi® long-read whole-genome sequencing into iHope’s international network.
iHope operates the world’s largest equitable rare-disease genomic testing network, supporting more than 1,000 patients annually through 25 clinical sites across 14 countries. The program is designed to enable collaborative, multi-technology support for rare disease patients, bringing together diverse approaches and clinical expertise to address the biological complexity of rare genetic disorders. The addition of PacBio’s HiFi long-read whole-genome sequencing aims to expand the range of genomic insights available across the network, providing data that supports iHope’s mission to ultimately drive more diagnostic clarity.
“We've been impressed with the progress iHope has made in getting answers for rare disease patients through the use of genomics and we believe HiFi Long-Read WGS can move the needle even more by finding variants that may have been otherwise missed,” said Christian Henry, President and Chief Executive Officer, PacBio. “HiFi long-read sequencing offers a complete view of the genome, and through this collaboration we aim to help expand iHope’s access to more comprehensive and advanced genomic research technologies that may help support its delivery of precision care. As February is Rare Disease Month, we’re reminded that every patient matters and we’re proud to support iHope’s efforts to help bring clarity and hope.”
By integrating PacBio long-read sequencing alongside diagnostic approaches, iHope will strengthen its ability to interrogate challenging regions of the genome and explore additional classes of genetic variation. PacBio and iHope aim to broaden opportunities for patients with unresolved findings, while reinforcing a shared learning environment in which advances at one laboratory or clinical site can inform and elevate care across the entire network. The PacBio - iHope collaboration is designed to support future research into precision therapeutic approaches, including antisense oligonucleotide–based strategies.
“We are delighted to welcome PacBio to the iHope network. This collaboration will further advance our mission to deliver diagnoses to families who have historically lacked access to advanced genomic tools,” said Ryan J. Taft, Chief Scientific Officer, Genetic Alliance. “Our experience shows that access to advanced genomic technologies, like PacBio’s long-read genomes, can profoundly and positively impact patient lives across diverse populations and geographies.”
Integration of PacBio HiFi sequencing into the iHope network is expected to begin in early 2026.
About PacBio
PacBio (NASDAQ: PACB) is a premier life science technology company that designs, develops, and manufactures advanced sequencing solutions to help scientists and clinical researchers resolve genetically complex problems. Our products and technologies, which include our HiFi long-read sequencing, address solutions across a broad set of research applications including human germline sequencing, plant and animal sciences, infectious disease and microbiology, oncology, and other emerging applications. For more information, please visit www.pacb.com and follow @PacBio.
PacBio products are provided for Research Use Only. Not for use in diagnostic procedures.
About Genetic Alliance
Genetic Alliance is a nonprofit health advocacy organization founded in 1986 to improve health through genetics and genomics. With a global network of thousands of disease-specific organizations, research institutions, clinicians, and industry partners, Genetic Alliance works to ensure that individuals and families—especially those affected by genetic and rare conditions—have access to accurate information, appropriate care, and meaningful participation in research.
iHope is a flagship program of Genetic Alliance that provides no-cost clinical genome and exome sequencing for children with suspected genetic conditions who lack access to testing due to geography or resources. iHope was launched by Illumina, Inc, Founding Partner and current Platinum Sponsor of iHope, and builds on Illumina’s clinical sequencing expertise. The program is designed to be scalable, ethical, patient-first and focused on individuals with limited access to genomic medicine. Through a global network of partner laboratories and clinical sites, iHope prioritizes diagnosing the undiagnosed, supporting families after results are returned, and empowering participants with control over their own genomic data.
For more information, visit www.geneticalliance.org.
Forward-Looking Statements
This press release may contain “forward-looking statements” within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and the U.S. Private Securities Litigation Reform Act of 1995. All statements other than statements of historical fact are forward-looking statements, including statements relating to: the availability, uses, accuracy, advantages, quality or performance of, or benefits of using, or expected benefits of using, PacBio products or technologies, including in connection with the iHope collaboration to, among other things, expand the range of genomic insights across its network, drive diagnostic clarity, interrogate challenging regions of the genome, explore additional classes of genetic variation and find variants that may otherwise be missed, support its delivery of precision care and expand its access to more comprehensive genomic sequencing technologies, broaden opportunities for patients with unresolved findings, and support research into precision therapeutic approaches; expectations with respect to the timing to integrate PacBio HiFi sequencing into the iHope network; and other future events. You should not place undue reliance on forward-looking statements because they are subject to assumptions, risks, and uncertainties and could cause actual outcomes and results to differ materially from currently anticipated results, including, challenges inherent in sequencing a large number of genomes, the difficulty of generating discoveries in new areas of research; potential product performance and quality issues; rapidly changing technologies and extensive competition in, and potential FDA regulatory issues relating to, genomic sequencing; unanticipated increases in costs or expenses; interruptions or delays in the supply of components or materials for, or manufacturing of, PacBio products and products under development; third-party claims alleging infringement of patents and proprietary rights or seeking to invalidate PacBio's patents or proprietary rights, among others. Additional factors that could materially affect actual results can be found in PacBio's most recent filings with the Securities and Exchange Commission, including PacBio's most recent reports on Forms 8-K, 10-K, and 10-Q, and include those listed under the caption "Risk Factors." These forward-looking statements are based on current expectations and speak only as of the date hereof; except as required by law, PacBio disclaims any obligation to revise or update these forward-looking statements to reflect events or circumstances in the future, even if new information becomes available.
Contacts
Investors:
ir@pacb.com
Media:
pr@pacb.com
FAQ
What did PacBio announce about joining iHope on February 12, 2026 (PACB)?
How many patients and sites will benefit from PacBio HiFi integration in the iHope network (PACB)?
When will PacBio's HiFi sequencing be integrated into iHope (PACB)?
What diagnostic benefits does PacBio HiFi long-read WGS bring to iHope patients (PACB)?
Will the PacBio–iHope collaboration support therapeutic research (PACB)?
